# The Efficacy and Safety of Keverprazan for Helicobacter Pylori Eradication

> **NCT06777732** · EARLY_PHASE1 · NOT_YET_RECRUITING · sponsor: **Nanjing First Hospital, Nanjing Medical University** · enrollment: 672 (estimated)

## Conditions studied

- Helicobacter Pylori Infection

## Interventions

- **DRUG:** Keverprazan
- **DRUG:** Amoxicillin
- **DRUG:** Furazolidone
- **DRUG:** Colloidal Bismuth Pectin

## Key facts

- **NCT ID:** NCT06777732
- **Lead sponsor:** Nanjing First Hospital, Nanjing Medical University
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-03
- **Primary completion:** 2025-09
- **Final completion:** 2026-01
- **Target enrollment:** 672 (ESTIMATED)
- **Last updated:** 2025-01-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06777732

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06777732, "The Efficacy and Safety of Keverprazan for Helicobacter Pylori Eradication". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT06777732. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*